查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球下呼吸道治疗药物市场 - 2023-2030年
市场调查报告书
商品编码
1290356

全球下呼吸道治疗药物市场 - 2023-2030年

Global Lower Respiratory Tract Therapeutics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球下呼吸道治疗法市场规模在2022年达到323.129亿美元，预计到2030年将见证有利可图的增长，达到562.517亿美元。在预测期内（2023-2030年），全球下呼吸道治疗法市场预计将呈现7.3%的复合年增长率。关键的市场趋势是行业中与吸烟有关的和吸烟的呼吸道疾病普遍增加。

例如，在2023年4月，密苏里州的运动推出了 "烟草正在改变"，以教育父母不同的糖果味烟草产品诱惑儿童成瘾。这也是烟草业的现实 - 尤其是在涉及电子烟的时候。

下呼吸道治疗学专注于下呼吸道感染疾病和紊乱的诊断、治疗和管理 这些感染是产科间接死亡的重要原因。怀孕的病人出现呼吸衰竭和肺水肿等并发症的风险增加。下呼吸道治疗药物旨在解决一系列的呼吸道疾病，如哮喘、慢性阻塞性肺病、呼吸道感染、囊性纤维化等。

下呼吸道治疗剂市场的驱动因素包括：下呼吸道疾病发病率的增加、老龄人口的增加、认识和诊断的提高、政府倡议和医疗政策、环境因素（如空气污染、气候变化和过敏原）以及技术进步。

例如，2023年4月，世界卫生组织（WHO）发布了《普及结核病快速诊断法》，为实现普及WHO推荐的快速诊断法（WRD）设定了基准，以增加细菌学证实的结核病和耐药性的检测，并缩短诊断时间。世卫组织推荐的快速诊断法具有高度的准确性和成本效益，缩短了开始治疗的时间，并影响到对病人重要的结果。

市场动态

下呼吸道疾病的发病率不断增加

下呼吸道疾病发病率的增加是在预测期内推动市场份额的主要因素。下呼吸道疾病，如哮喘、慢性阻塞性肺病（COPD）、肺炎和支气管炎，给全球医疗系统带来了巨大负担。这些疾病的发病率越来越高，意味着需要有效疗法的患者人数越来越多，导致市场需求增加。

例如，2023年5月，血浆衍生药物和创新诊断解决方案的全球领导者Grifols宣布，它推出了AlphaID家庭遗传健康风险服务（AlphaID At Home），这是美国有史以来第一个免费直接面向消费者的项目，用于筛查慢性阻塞性肺病的遗传风险。

不良反应的风险更高

与下呼吸道治疗药物有关的不良反应，如用于治疗哮喘或慢性阻塞性肺病的药物，会引起患者和医护人员的安全担忧。不良反应的风险可能使患者不愿意开始或继续治疗，导致疾病管理不理想，市场需求减少。

对下呼吸道治疗药物的安全状况进行持续监测，对于有效识别和管理不良反应至关重要。药物警戒工作有助于确保早期发现和适当管理不良反应，维持病人的信心和市场需求。

COVID-19影响分析

COVID-19大流行病对医疗保健行业，包括下呼吸道治疗药物市场产生了深远影响。虽然这场大流行强调了呼吸道健康的重要性，但它也转移了对其他呼吸道疾病的资源和注意力。此外，供应链、临床试验和医疗服务的中断也给市场带来了挑战。

这场大流行扰乱了正在进行的下呼吸道治疗药物的临床试验。许多试验被暂停、推迟或修改，以优先考虑COVID-19的研究并确保病人安全。这种临床试验活动的中断可能会推迟新疗法的开发和监管部门的批准，影响下呼吸道疗法的未来管道。

俄罗斯-乌克兰冲突分析

俄乌冲突对下呼吸道治疗剂市场产生了重大影响。战争可能扰乱研发活动，包括新疗法或临床试验的开发。有限的资源、基础设施的破坏和研究人员的流离失所会阻碍呼吸道治疗剂研究的进展。

冲突可能导致公共卫生方面的挑战，包括由于过度拥挤、卫生条件差和流离失所而导致呼吸道感染的风险增加。这些因素会导致呼吸道疾病的负担加重，可能需要增加获得下呼吸道治疗药物的机会。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按疾病类型简述
  • 按药物类别分类
  • 按给药途径分类
  • 按分销渠道分类
  • 按终端用户分类
  • 按地区分类

第4章：动态变化

  • 影响因素
    • 驱动因素
      • 下呼吸道疾病的发病率不断上升
      • 有害的环境因素
    • 限制因素
      • 不良反应的风险较高
      • 治疗方案有限
    • 机会
      • 治疗程序的技术进步
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按疾病类型

  • 哮喘病
  • 慢性阻塞性肺病
  • 肺炎
  • 结核病
  • 支气管炎
  • 其他

第8章：按药物类别划分

  • 抗生素
  • 非甾体类抗炎药
  • 止咳药
  • 鼻腔减充血剂
  • 其他药物

第9章：按给药途径分类

  • 口服
  • 静脉注射
  • 其他途径

第十章：按分销渠道分类

  • 医院药房
  • 零售药店
  • 网上药店

第十一章：按终端用户分类

  • 医院
  • 专科诊所
  • 家庭护理
  • 其他

第十二章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第13章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十四章：公司简介

  • F. Hoffmann-La Roche Ltd.
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc

第十五章 ：附录

简介目录
Product Code: PH558

Market Overview

The Global Lower Respiratory Tract Therapeutics Market size reached US$ 32,312.9 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 56,251.7 million by 2030. The global lower respiratory tract therapeutics market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030). The key market trend is the widespread increase in industry smoke-related and smoking respiratory diseases.

For instance, in April 2023, Missouri's campaign launched "Tobacco is Changing", to educate parents about the different candy-flavored tobacco products tempting children into addiction. It is also the reality of the tobacco landscape - especially when it comes to e-cigarettes.

Lower respiratory tract therapeutics focuses on the diagnosis, treatment, and management of diseases and disorders of lower respiratory tract infections These infections are an important cause of indirect obstetric death. Pregnant patients are at increased risk of complications such as respiratory failure and empyema. Lower respiratory tract therapeutics are designed to address a range of respiratory conditions such as asthma, COPD, respiratory infections, cystic fibrosis and so on.

The lower respiratory tract therapeutics market is driven by factors such as the increasing prevalence of lower respiratory tract diseases, the rising aging population, increasing awareness and diagnosis, government initiatives and healthcare policies, environmental factors (such as air pollution, climate change, and allergens), and technological advancements.

For instance, in April 2023, The World Health Organization (WHO) released Universal access to rapid tuberculosis diagnostics, setting benchmarks to achieve universal access to WHO-recommended rapid diagnostics (WRDs) to increase bacteriologically-confirmed TB and detection of drug resistance and reduce the time to diagnosis. WHO-recommended rapid diagnostics are highly accurate, cost-effective, reduce the time to treatment initiation, and impact patient-important outcomes.

Market Dynamics

Increasing Prevalence Of Lower Respiratory Tract Diseases

The increasing prevalence of lower respiratory tract diseases is the major factor driving the market share during the forecast period. Lower respiratory tract diseases, such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and bronchitis, impose a significant burden on global healthcare systems. The growing prevalence of these diseases means a larger patient population in need of effective therapeutics, leading to increased market demand.

For instance, in May 2023, Grifols, a global leader in plasma-derived medicines and innovative diagnostic solutions, announced that it launched its AlphaID at-home genetic health risk service (AlphaID At Home), the first-ever free direct-to-consumer program in the U.S., to screen for the genetic risk of COPD.

Higher Risk Of Adverse Effects

Adverse effects associated with lower respiratory tract therapeutics, such as medications used for asthma or COPD, can raise safety concerns among patients and healthcare professionals. The risk of adverse effects may discourage patients from initiating or continuing treatment, leading to suboptimal disease management and reduced market demand.

Continuous monitoring of the safety profile of lower respiratory tract therapeutics is crucial to identify and manage adverse effects effectively. Pharmacovigilance efforts help ensure early detection and appropriate management of adverse effects, maintaining patient confidence and market demand.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a profound impact on the healthcare industry, including the lower respiratory tract therapeutics market. While the pandemic has highlighted the importance of respiratory health, it has also diverted resources and attention away from other respiratory conditions. Additionally, disruptions in supply chains, clinical trials, and healthcare services have posed challenges for the market.

The pandemic has disrupted ongoing clinical trials for lower respiratory tract therapeutics. Many trials were paused, delayed, or modified to prioritize COVID-19 research and ensure patient safety. This interruption in clinical trial activities may delay the development and regulatory approval of new therapies, affecting the future pipeline of lower respiratory tract therapeutics.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had a significant impact on the lower respiratory tract therapeutics market. The war may disrupt research and development activities, including the development of new therapies or clinical trials. Limited resources, infrastructure damage, and the displacement of researchers can hinder progress in respiratory therapeutics research.

The conflict can contribute to public health challenges, including the increased risk of respiratory infections due to overcrowding, poor sanitation, and displacement. These factors can lead to a higher burden of respiratory diseases and may require increased access to lower respiratory tract therapeutics.

Segment Analysis

The global lower respiratory tract therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, end-user, and region.

Based on Disease Type, The Asthma Therapeutics Segment Is Expected To Dominate The Market Share

The market for asthma therapeutics held 45.3% of the global lower respiratory tract therapeutics market share in 2022. Asthma is a prevalent chronic respiratory condition affecting millions of people worldwide. The high prevalence of asthma contributes to a larger patient population requiring ongoing management and treatment, which drives the demand for asthma therapeutics.

Asthma management involves a range of therapeutics to control and prevent symptoms. These include bronchodilators (both short-acting and long-acting), inhaled corticosteroids, combination inhalers, leukotriene modifiers, and monoclonal antibodies targeting specific inflammatory pathways. The availability of multiple treatment options within the asthma therapeutics segment provides choices for healthcare professionals to tailor treatment plans to individual patient needs.

For instance, in May 2023, Alkem Laboratories, a leading pharmaceutical company, announced the launch of its initiative 'Reliever Free India' to raise awareness about Asthma among physicians and Asthma patients. This initiative aims to spread awareness of the hazards of over-usage of reliever medications and substitute it with SMART therapy i.e., needing only one inhaler for both 'daily' and 'reliever' asthma treatment.

Geographical Analysis

North America Holds The Largest Market Share Due To The High Disease Burden And Technological Advancements

North America held 38.1% market share for the lower respiratory tract therapeutics market in 2022 due to the high disease burden and technological advancements in treatment options. North America has a significant burden of lower respiratory tract diseases, including asthma, COPD, and respiratory infections. The region's population, lifestyle factors, environmental exposures, and healthcare infrastructure contribute to the prevalence of these conditions.

North America has witnessed significant technological advancements in the field of respiratory medicine. This includes the development of advanced inhalation devices, targeted biologics, digital health solutions, and precision medicine approaches for lower respiratory tract diseases. These technological advancements enhance treatment efficacy, patient convenience, and disease management, further strengthening the market share of North America.

Competitive Landscape

The major global players in the market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi S.A, Pfizer Inc., GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc.

Why Purchase the Report?

  • To visualize the global lower respiratory tract therapeutics market segmentation based on disease type, drug class, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of lower respiratory tract therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global lower respiratory tract therapeutics market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of lower respiratory tract diseases
      • 4.1.1.2. Harmful environmental factors
    • 4.1.2. Restraints
      • 4.1.2.1. Higher risk of adverse effects
      • 4.1.2.2. Limited treatment options
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements in treatment procedures
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Asthma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. COPD
  • 7.4. Pneumonia
  • 7.5. Tuberculosis
  • 7.6. Bronchitis
  • 7.7. Others

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Antibiotics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Non-Steroidal Anti-Inflammatory Drugs
  • 8.4. Cough Suppressants
  • 8.5. Nasal Decongestants
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By End-User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.1.2. Market Attractiveness Index, By End-User
  • 11.2. Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Specialty Clinics
  • 11.4. Homecare
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. The UK
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. F. Hoffmann-La Roche Ltd.
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Teva Pharmaceutical Industries Ltd.
  • 14.3. Sanofi S.A
  • 14.4. Pfizer Inc.
  • 14.5. GSK plc
  • 14.6. Novartis AG
  • 14.7. AstraZeneca
  • 14.8. Johnson & Johnson Private Limited
  • 14.9. Sun Pharmaceutical Industries Ltd.
  • 14.10. Merck & Co., Inc

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us